Wockhardt announced that its novel intravenous antibiotic Foviscu (WCK 4282) has successfully met the primary endpoint in a Phase 3 clinical trial in patients with complicated urinary tract infections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results